Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Guards Nexium Patent, Takes Teva, Cipla To New Jersey Court

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - AstraZeneca, the maker of world's second largest selling drug brand Nexium (esomperazole) is going all out to protect the patent covering its popular anti-ulcer medicine

You may also be interested in...



Ranbaxy-AstraZeneca Pact Part Of Indian Drug Maker Trend

The patent-dispute settlement Ranbaxy Pharmaceuticals reached with AstraZeneca reflects a new Indian trend beyond the business of making generics. The settlement terms include Ranbaxy selling AstraZeneca's Nexium (esomeprazole) when the first of several patents expires in 2014. Like other Indian drug makers, Ranbaxy is expanding beyond the generics market to improve its research and development capabilities and make a dent in the branded drugs market. Ranbaxy plans to split its generics and branded efforts this summer, a move being taken by several Indian competitors with similar plans. (Click here for more

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel